PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype. PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006. RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001). A similar pattern was observed for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004). Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001). Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90). CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk. Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.
PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype. PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006. RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001). A similar pattern was observed for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004). Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001). Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90). CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk. Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.
Authors: Lynn R Goldin; Ola Landgren; Mary L McMaster; Gloria Gridley; Kari Hemminki; Xinjun Li; Lene Mellemkjaer; Jørgen H Olsen; Martha S Linet Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-10 Impact factor: 4.254
Authors: John A Curtin; Jane Fridlyand; Toshiro Kageshita; Hetal N Patel; Klaus J Busam; Heinz Kutzner; Kwang-Hyun Cho; Setsuya Aiba; Eva-Bettina Bröcker; Philip E LeBoit; Dan Pinkel; Boris C Bastian Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine van Glabbeke; Hanneke C Kluin-Nelemans Journal: Haematologica Date: 2006-10-17 Impact factor: 9.941
Authors: Lindsay M Morton; Patricia Hartge; Theodore R Holford; Elizabeth A Holly; Brian C H Chiu; Paolo Vineis; Emanuele Stagnaro; Eleanor V Willett; Silvia Franceschi; Carlo La Vecchia; Ann Maree Hughes; Wendy Cozen; Scott Davis; Richard K Severson; Leslie Bernstein; Susan T Mayne; Fred R Dee; James R Cerhan; Tongzhang Zheng Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-04 Impact factor: 4.254
Authors: Christine F Skibola; Paige M Bracci; Alexandra Nieters; Angela Brooks-Wilson; Silvia de Sanjosé; Ann Maree Hughes; James R Cerhan; Danica R Skibola; Mark Purdue; Eleanor Kane; Qing Lan; Lenka Foretova; Maryjean Schenk; John J Spinelli; Susan L Slager; Anneclaire J De Roos; Martyn T Smith; Eve Roman; Wendy Cozen; Paolo Boffetta; Anne Kricker; Tongzhang Zheng; Tracy Lightfoot; Pierluigi Cocco; Yolanda Benavente; Yawei Zhang; Patricia Hartge; Martha S Linet; Nikolaus Becker; Paul Brennan; Luoping Zhang; Bruce Armstrong; Alex Smith; Renee Shiao; Anne J Novak; Marc Maynadie; Stephen J Chanock; Anthony Staines; Theodore R Holford; Elizabeth A Holly; Nathaniel Rothman; Sophia S Wang Journal: Am J Epidemiol Date: 2010-01-04 Impact factor: 4.897
Authors: Nadejda Y Mudie; Anthony J Swerdlow; Craig D Higgins; Paul Smith; Zongkai Qiao; Barry W Hancock; Peter J Hoskin; David C Linch Journal: J Clin Oncol Date: 2006-03-06 Impact factor: 44.544
Authors: P Brennan; G Scélo; K Hemminki; L Mellemkjaer; E Tracey; A Andersen; D H Brewster; E Pukkala; M L McBride; E V Kliewer; J M Tonita; A Seow; V Pompe-Kirn; C Martos; J G Jonasson; D Colin; P Boffetta Journal: Br J Cancer Date: 2005-07-11 Impact factor: 7.640
Authors: Megan M Herr; Sara J Schonfeld; Graça M Dores; Diana R Withrow; Margaret A Tucker; Rochelle E Curtis; Lindsay M Morton Journal: J Natl Cancer Inst Date: 2018-11-01 Impact factor: 13.506
Authors: Loretta J Nastoupil; Peter McLaughlin; Lei Feng; Sattva S Neelapu; Felipe Samaniego; Fredrick B Hagemeister; Ana Ayala; Jorge E Romaguera; Andre H Goy; Eleanor Neal; Michael Wang; Luis Fayad; Michelle A Fanale; Yasuhiro Oki; Jason R Westin; Maria A Rodriguez; Fernando Cabanillas; Nathan H Fowler Journal: Br J Haematol Date: 2017-03-24 Impact factor: 6.998
Authors: Geffen Kleinstern; Abdul Rishi; Sara J Achenbach; Kari G Rabe; Neil E Kay; Tait D Shanafelt; Wei Ding; Joe F Leis; Aaron D Norman; Timothy G Call; James R Cerhan; Sameer A Parikh; Christian L Baum; Susan L Slager Journal: J Am Acad Dermatol Date: 2020-07-16 Impact factor: 11.527
Authors: Clémentine Sarkozy; Matthew J Maurer; Brian K Link; Hervé Ghesquieres; Emmanuelle Nicolas; Carrie A Thompson; Alexandra Traverse-Glehen; Andrew L Feldman; Cristine Allmer; Susan L Slager; Stephen M Ansell; Thomas M Habermann; Emmanuel Bachy; James R Cerhan; Gilles Salles Journal: J Clin Oncol Date: 2018-11-27 Impact factor: 44.544
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959